Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen
about
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccinationOptimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccinesEnhancing Human Immunodeficiency Virus-Specific CD8(+) T Cell Responses with Heteroclitic PeptidesT-cell Receptor-optimized Peptide Skewing of the T-cell Repertoire Can Enhance Antigen TargetingStructural and Functional Correlates of Enhanced Antiviral Immunity Generated by Heteroclitic CD8 T Cell EpitopesProline substitution independently enhances H-2D(b) complex stabilization and TCR recognition of melanoma-associated peptidesIdentification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine ConsortiumUsing X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens.Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognitionIntranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanomaSingle cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypesNew approaches to design HIV-1 T-cell vaccinesProfile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination.Dendritic-cell-based therapeutic cancer vaccinesPitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapyImproving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor.Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvantConditional superagonist CTL ligands for the promotion of tumor-specific CTL responses.Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses.Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo.Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines.Immunotherapy of cancer in 2012.Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens.Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosisAn Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8α Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT.Single naive CD4+ T cells from a diverse repertoire produce different effector cell types during infection.A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor CellsImproving T cell responses to modified peptides in tumor vaccinesHeterogeneity assessment of functional T cell avidity.Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses.Structural and dynamic control of T-cell receptor specificity, cross-reactivity, and binding mechanism.Mobilizing and evaluating anticancer T cells: pitfalls and solutions.Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer ImmunityEngineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potencyGeneration of cytotoxic T lymphocytes specific for native or modified peptides derived from the epidermal growth factor receptor pathway substrate 8 antigen.
P2860
Q24652965-660E6167-1FCC-4C35-BBAA-392087A9C788Q26738680-D51C30CC-8CE5-4F6A-8519-C1436AA5B3F5Q26800123-A76EF398-2D84-4412-9342-AB734BE70750Q27672418-34A7A857-DE54-4D43-97BD-E1C73B772381Q27683638-574AF702-882A-41ED-A802-1C6AB60D70BFQ27685375-6C9CE5BE-171C-43F4-B1B7-E9E49B2B9C25Q30418879-980FAE9F-93CB-40EA-99CF-CDF765FB825CQ30439109-83FBEB4C-12F4-4C28-BAAC-6D7AD77327B7Q33613320-CEA46616-45CB-41AF-80BF-4E80AB5D9D85Q33635226-58DD1B01-59F6-42DD-A583-D3AEAA61A0ECQ33731220-50D1934A-90E4-4C56-868E-1E8F62D7B8DBQ34005128-FA27F9FC-E27A-4E85-B2FF-DB29F3E12A0BQ34274849-0B83AB72-4898-4EBA-8BCB-E7760295DCDEQ34338725-D965ACDD-644C-4A6E-AEB1-A65E8AFB1712Q34360094-57935D0A-CAAF-4E84-B82C-2528518F47A2Q34508125-C94055A7-6F3B-4DFB-A766-F1C617D15B7CQ34594769-5D13973C-A6D8-4FBA-B923-BD9C4EA48E6EQ35012363-4635DA10-A1D7-4D2E-8273-34855C2D1FD8Q35125382-0DBBB54B-3838-42CD-A070-D2C6CF7C8739Q35855820-13F419F1-6349-401D-9C4B-41BF8E8BAE40Q35906719-F670E5EA-D53C-42F7-B997-718088026751Q36057468-415595DE-37ED-4122-A128-7DA8DE06505DQ36080586-FBCD7C73-C116-486B-96F8-B414E52A0345Q36137249-9F9EA4BC-BF95-49A9-BC77-85B3509C5F01Q36243536-8A86F4C1-3FC3-4669-8006-BC76D09C51E4Q36510860-3014F2E4-886A-4AE1-925B-110698039827Q36547213-95D7754D-681B-43C0-A570-6ABCFC13235BQ36982831-749E99AA-B64E-41B2-839F-72E0D6642E20Q37145706-EBF8ED4A-7728-4982-B9C6-B0ED34C7EA8CQ37155667-234DB9A3-7A14-4E6C-9AB2-FED464585C88Q37214957-EFE26758-6F8C-44DB-B469-9E916739F54AQ37634253-26A9DE33-ECBA-4E91-939F-0C193CC8040EQ37695291-9728E2AA-55A6-4656-A8CB-D41654A38CE7Q37729146-08FE29A9-FC38-4422-9F9A-A298264F7AC0Q38050477-D4313403-F867-493F-9F4B-AEE7A1E539A6Q38152795-05ACC823-84CB-4C17-8FE3-FB2F85EE1FAEQ38174601-C0C4A4F9-F762-4782-8513-2FA40AF94532Q38231581-B9813DC8-97CF-4A3C-AF28-F4E518B54DC6Q38671405-14E705D3-2D8B-4008-A0C1-9868BC2A13FFQ38942201-25637352-93A9-4623-A9A7-F173E63963E8
P2860
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Unmodified self antigen trigge ...... eactivity than altered antigen
@ast
Unmodified self antigen trigge ...... eactivity than altered antigen
@en
Unmodified self antigen trigge ...... activity than altered antigen.
@nl
type
label
Unmodified self antigen trigge ...... eactivity than altered antigen
@ast
Unmodified self antigen trigge ...... eactivity than altered antigen
@en
Unmodified self antigen trigge ...... activity than altered antigen.
@nl
prefLabel
Unmodified self antigen trigge ...... eactivity than altered antigen
@ast
Unmodified self antigen trigge ...... eactivity than altered antigen
@en
Unmodified self antigen trigge ...... activity than altered antigen.
@nl
P2093
P2860
P356
P1476
Unmodified self antigen trigge ...... eactivity than altered antigen
@en
P2093
Catherine Barbey
Daniel E Speiser
Estelle Devevre
Nathalie Rufer
Pedro Romero
Petra Baumgaertner
Verena Voelter
P2860
P304
P356
10.1073/PNAS.0800080105
P407
P577
2008-03-04T00:00:00Z